Paradigm Biopharmaceuticals (ASX:PAR) appointed Daniel Furtner as its Chief Medical Officer, effective Wednesday, according to a Tuesday Australian bourse filing.
Furtner succeeds Donna Skerrett, who will remain with the firm as a senior scientific advisor.
Furtner previously served as the senior director of medical affairs for the Asia Pacific region at CSL.
Its shares fell 2% in recent trading on Tuesday.